Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

ere were 4 SAEs in 3 subjects (2 embolism, toe gangrene, pain in thigh).

All SAEs out of all studies using AMG0001 were evaluated by the DSMB (Data Safety Monitoring Board) and it was concluded that, as of today, there is no major safety concern related to AMG0001.

While significant improvement was confirmed based on the efficacy evaluation, as AMG0001 is a highly novel therapeutic, AnGes will continue development by carefully following the safety.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

About AnGes MG

AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on innovative discoveries by researchers of Osaka University. The company specializes in research and development and practical application of DNA-based therapeutics. The company, along with its subsidiaries, is engaged in developing three new medicines: HGF genetic medicine which improves blood circulation by regeneratin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
(Date:3/5/2015)... , March 5, 2015 BioLineRx ... clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... has commenced an underwritten public offering of American ... its Ordinary Shares. All of the ADSs in ... JMP Securities is acting as ...
(Date:3/5/2015)... MOUNTAIN VIEW, Calif., March 5, 2015  IRIDEX Corporation (Nasdaq: ... fourth quarter and year ended January 3, 2015.  ... 2014, a record for the Company and up 11% from ... were $42.8 million, also a record, up 12% from $38.3 ... fourth quarter was 50.1%, up from 48.6% in the fourth ...
Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... March 06, 2015 Jvion, the ... release of a Clostridium Difficile (C Diff) predictive ... C Diff use case is the latest in ... hospital acquired infections, chronic conditions, and individual illnesses. ... C Diff solution flags at risk individuals to ...
(Date:3/6/2015)... NC (PRWEB) March 06, 2015 In a ... of Polish mesothelioma patients reported that shoulder pain was their ... story on its website. Click here to read it ... Warsaw analyzed the medical records of 49 mesothelioma patients ... them reported that it was shoulder pain that first prompted ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2
... finds , FRIDAY, Nov. 2 (HealthDay News) -- Radiation seed ... prostate cancer in men 60 and younger as they are ... is a minimally invasive procedure in which small radioactive seeds ... time after seed implantation is much shorter than surgery, and ...
... a leading global antibody manufacturer, announced today the,company,s continued ... San Diego, California, November 3 - 7, 2007. ... half, the influx of meeting,participants will hopefully provide a ... region. "All of the staff at ABR-Affinity BioReagents is,hopeful ...
... American Medical Women,s,Association (AMWA) today voiced support for ... Detection Coverage Act of 2007, that would,give older ... techniques. The bill, H.R. 4055, was introduced by ... testing for the human,papillomavirus (HPV), in conjunction with ...
... surgery feel less pain and leave the hospital ... that delivers local anesthetic agents and,blocks pain transmission ... The Children,s Hospital of Philadelphia adapted the technique,for ... November 2007 issue of the journal,Anesthesia & Analgesia. ...
... 2 Staff and board,members of Delaware Hospice honored ... RN, for 20 years of service at the annual,Staff ... Delaware Hospice from a fledgling,grassroots organization to what it ... with quality and compassion., In 1987, the five-year ...
... Guest Appearances by Ciara, Kelly Rowland, Common, Romeo and Lyfe ... ... Networks today announced that,their award-winning national HIV/AIDS public information campaign with the,Kaiser ... special, "WHAT U KNOW BOUT THAT? RAP-IT-UP SEX,QUIZ" slated to premiere on ...
Cached Medicine News:Health News:Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer 2Health News:ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007 2Health News:American Medical Women's Association Supports New Bill That Requires Medicare Coverage of HPV Testing as Part of Cervical Cancer Screening 2Health News:American Medical Women's Association Supports New Bill That Requires Medicare Coverage of HPV Testing as Part of Cervical Cancer Screening 3Health News:Anesthesia Pouch Allows Children to Go Home Sooner After Surgery 2Health News:Anesthesia Pouch Allows Children to Go Home Sooner After Surgery 3Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 2Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 3Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 2Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 3Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: